LPCN vs. VTGN, SRZN, SKYE, MNOV, ZURA, BYSI, IMRX, IMUX, ZIVO, and XCUR
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Vistagen Therapeutics (VTGN), Surrozen (SRZN), Skye Bioscience (SKYE), MediciNova (MNOV), Zura Bio (ZURA), BeyondSpring (BYSI), Immuneering (IMRX), Immunic (IMUX), ZIVO Bioscience (ZIVO), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs. Its Competitors
Lipocine (NASDAQ:LPCN) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
9.1% of Lipocine shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Lipocine has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -6,777.08%. Lipocine's return on equity of -19.17% beat Vistagen Therapeutics' return on equity.
Lipocine presently has a consensus price target of $9.00, suggesting a potential upside of 172.73%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Vistagen Therapeutics.
Lipocine received 67 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 66.86% of users gave Lipocine an outperform vote.
Lipocine has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Lipocine has higher revenue and earnings than Vistagen Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lipocine had 8 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 9 mentions for Lipocine and 1 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.87 beat Lipocine's score of 0.29 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
Summary
Lipocine beats Vistagen Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy LPCN Stock Free LPCN Stock Alerts